Welcome to the BeiGeneius hemato-oncology and lung cancer page

BeiGeneius is an expert-led educational program exploring key developments 
in hemato-oncology and lung cancers, and represents a forum for learning and exchange. 
Explore clinically relevant content, including on-demand webinars and discussions, patient case studies, and bite-sized updates via our Spotlight Series.

Webinars

Explore educational content in hemato-oncology and lung cancers delivered by global experts. Browse previous webinar recordings on-demand, including navigable, chapterized content.

Global Experts Exchange

Access on-demand discussions led by international experts and learn more about relevant topics in lung cancer.

Summits

Access on-demand discussions led by international experts and learn more about relevant topics in hematology. 

Patient Cases

Enhance your understanding of patient care with our interactive case studies on the diagnosis and treatment of hematologic malignancies, covering both the frontline and relapsed/refractory settings.

Spotlight Series

Stay up-to-date with recent developments and best-practice in your field with these bite-sized updates from our experts.

Steering Committee Hematology

Meet the team of international experts behind all BeiGeneius content and activities.

Steering Committee Lung

Meet the team of international experts behind all BeiGeneius content and activities.

Expert Digest

Find out more about key topics in your field via short, digested overview pieces written by our experts.

Register for the next BeiGeneius Webinar

Coming soon!
The next BeiGeneius Webinar will be announced shortly.

In the meantime, browse previous webinar recordings on-demand.

Recent BeiGeneius Content

Chapters Duration 00:10
A multidisciplinary panel review the latest developments in R/R CLL and indolent lymphomas and share expert overviews of clinical trial interpretation and best practice in patient communication.
Chapters Duration 50:51
Stephan Stilgenbauer, Meletios Dimopoulos, and Stefano Luminari look back on ASH, highlighting developments with BTK inhibitor-based therapies in CLL and immunotherapies in FL.
Chapters Duration 18:30
Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen.